Lung cancer combo shows promise in Second-Line trial
NCT ID NCT01350817
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel) works better than chemotherapy alone for people with advanced non-small cell lung cancer whose first treatment stopped working. 156 participants were randomly assigned to one of two groups. The main goal was to see how long the cancer stayed under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- erlotinib and docetaxel
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with advanced non-small cell lung cancer, potentially delaying disease progression.
- What could go wrong
- This is a phase 2 trial with a modest sample size, so results may not be definitive. The combination may not improve survival and could increase side effects like rash or fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH de Meaux
Meaux, France
-
CHU Brest
Brest, France
-
CHU Reims
Reims, France
-
Clinique Pneumologique; Hôpital Charles Nicolle
Rouen, 76031, France
-
Département de Pathologie Respiratoire du CHU de Limoges
Limoges, France
-
Département des Maladies Respiratoires ; Hôpital Sainte Marguerite
Marseille, 13274, France
-
Hôpital Charles Nicolle, Service de Pneumologie
Rouen, France
-
Service de Pneumologie
Beauvais, France
-
Service de Pneumologie
Bordeaux, France
-
Service de Pneumologie
Charleville Mezière, France
-
Service de Pneumologie
Créteil, France
-
Service de Pneumologie
Draguignan, France
-
Service de Pneumologie
Elbeuf, France
-
Service de Pneumologie
Gap, France
-
Service de Pneumologie
Meaux, France
-
Service de Pneumologie
Mulhouse, France
-
Service de Pneumologie
Villefranche, France
-
Service de Pneumologie - Hôpital St Antoine, Paris
Paris, 75571, France
-
Service de Pneumologie ; Centre hospitalier
Charleville-Mézières, 08 000, France
-
Service de Pneumologie, CHU Angers
Angers, 49033, France
-
Service de Pneumologie, Hôpital Nord
Saint-Etienne, France
-
Service de Pneumologie, Hôpital Pontchailloux
Rennes, France
-
Service de Pneumologie, Hôpital de la Croix Rousse
Lyon, France
-
Service de Pneumologie-Allergologie; Centre Hospitalier Général
Périgueux, 24019, France
-
Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay
Mantes-la-Jolie, 78200, France
-
Service de Pneumologie; CHG de Roanne
Roanne, 42300, France
-
Service de Pneumologie; Centre Hospitalier
Beauvais, 60 021, France
-
Service de Pneumologie; Centre Hospitalier
Draguignan, 83300, France
-
Service de Pneumologie; Hôpital Bois Guillaume
Rouen, 76233, France
-
Service de pneumologie; Centre Hospitalier d'Annecy
Annecy, 74011, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?